Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes?
Edelman
Steve V
SV
VA San Diego Healthcare Center, Department of Endocrinology and Metabolism, 3350 La Jolla Village Drive (111G), San Diego, CA 92161, USA. svedelman@vapop.ucsd.edu
Garg
Satish
S
Kolterman
Orville G
OG
D000682:Amyloid / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006442:Glycated Hemoglobin; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D058228:Islet Amyloid Polypeptide
D000682:Amyloid; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D006454:Hemoglobins; D007004:Hypoglycemic Agents; D007328:Insulin; D058228:Islet Amyloid Polypeptide; C517652:hemoglobin A1c protein, human; C105254:pramlintide